Protara Therapeutics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 40.42 million compared to USD 65.95 million a year ago. Basic loss per share from continuing operations was USD 3.57 compared to USD 5.86 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.925 USD | -4.10% | +10.80% | +55.99% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+55.99% | 33.44M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- TARA Stock
- News Protara Therapeutics, Inc.
- Protara Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023